Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …

Inflammatory bowel disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis
(UC), is characterized by inflammation of the gastrointestinal tract. In UC, inflammation is …

Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …

Crohn's disease and ulcerative colitis are two idiopathic inflammatory disorders of the GI
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …

Over the last 2 decades, novel therapies targeting several immune pathways have been
developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti …

Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in
which dysregulated immune responses cause persistent inflammation of the gut mucosa …

Antitumor necrosis factor α (anti-TNF) agents have dramatically influenced management of
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …

The inflammatory bowel diseases (IBD), notably Crohn's disease (CD) and ulcerative colitis
(UC), are systemic inflammatory diseases primarily involving the gastrointestinal tract …

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Background Tumour necrosis factor (TNF)‐alpha inhibitors are a major advance in the
management of inflammatory bowel disease but increase the risk for tuberculosis (TB). Aim …